Have a personal or library account? Click to login
Mesenchymal Stem Cell (MSCs) Therapy for Ischemic Heart Disease: A Promising Frontier Cover

Mesenchymal Stem Cell (MSCs) Therapy for Ischemic Heart Disease: A Promising Frontier

Global Heart
Volume 17 (2022): Issue 1
By: Merlin Sobia Poomani,  Iyyadurai Mariappan,  Ramachandran Perumal,  Rathika Regurajan,  Krishnaveni Muthan and  Venkatesh Subramanian  
Open Access
|Mar 2022

References

  1. 1Sans S, Kesteloot H, Kromhout D. Erratum. The burden of cardiovascular diseases mortality in Europe. Task force of the European society of cardiology on cardiovascular mortality and morbidity statistics in Europe. Eur Heart J. 1997; 18(10): 1680–1. DOI: 10.1093/oxfordjournals.eurheartj.a015434
    Back to article
  2. 2Sliwa K, Ntusi N. Battling cardiovascular diseases in a perfect storm: South Africa 25 years after Apartheid. Circulation. 2019; 139(14): 1658–60. DOI: 10.1161/CIRCULATIONAHA.118.038001
    Back to article
  3. 3Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol [Internet]. 2010; 35(2): 72–115. DOI: 10.1016/j.cpcardiol.2009.10.002
    Back to article
  4. 4Chow CM, Donovan L, Manuel D, Johansen HTJ. Regional variation in self-reported heart disease prevalence in canada. Can J Cardiol. 2005; 21(14): 1265–71.
    Back to article
  5. 5Giordano FJ, Giordano FJ. Review series Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest. 2005; 115(3): 500–8. DOI: 10.1172/JCI200524408
    Back to article
  6. 6Frangogiannis C, Steenbergen N. Chapter 36: Ischemic Heart disease. Hill JA, Olson EN (eds.), Muscle. Academic press. 2012; 495–521. DOI: 10.1016/B978-0-12-381510-1.00036-3
    Back to article
  7. 7Burchfield JS, Xie M, Hill JA. Pathological ventricular remodeling: Mechanisms: Part 1 of 2. Circulation. 2013; 128(4): 388–400. DOI: 10.1161/CIRCULATIONAHA.113.001878
    Back to article
  8. 8McKelvie RS, Moe GW, Ezekowitz JA, Heckman GA, Costigan J, Ducharme A, et al. The 2012 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Acute and Chronic Heart Failure. Can J Cardiol. 2013; 29(2): 168–81. DOI: 10.1016/j.cjca.2012.10.007
    Back to article
  9. 9Wells G, Parkash R, Healey JS, Talajic M, Arnold JM, Sullivan S, et al. Cardiac resynchronization therapy: A meta-analysis of randomized controlled trials. CMAJ. 2011; 183(4): 421–9. DOI: 10.1503/cmaj.101685
    Back to article
  10. 10Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, De Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002; 359(9311): 995–1003. DOI: 10.1016/S0140-6736(02)08089-3
    Back to article
  11. 11Madigan M, Atoui R. Therapeutic use of stem cells for myocardial infarction. Bioengineering. 2018; 5(2): 1–18. DOI: 10.3390/bioengineering5020028
    Back to article
  12. 12Williams AR, Hare JM. Mesenchymal stem cells: Biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 2011; 109(8): 923–40. DOI: 10.1161/CIRCRESAHA.111.243147
    Back to article
  13. 13Ma S, Xie N, Li W, Yuan B, Shi Y, Wang Y. Immunobiology of mesenchymal stem cells. Cell Death Differ. 2014; 21(2): 216–25. DOI: 10.1038/cdd.2013.158
    Back to article
  14. 14Pelacho B, Prosper F. Stem cells and cardiac disease: Where are we going? Curr Stem Cell Res Ther. 2008; 3(4): 265–76. DOI: 10.2174/157488808786734015
    Back to article
  15. 15Friedenstein AJ, Petrakova K, Kurolesova A, Frolova G. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968; 6(2): 230–47. DOI: 10.1097/00007890-196803000-00009
    Back to article
  16. 16Friedenstein AJ, Chailakhjan K, Lalykina K. The development of fibroblast colonies in monolayer cultures of guinea pig bone marrow and spleen cells. Cell Tissue Kinet. 1970; 3(4): 393–403. DOI: 10.1111/j.1365-2184.1970.tb00347.x
    Back to article
  17. 17Friedenstein AJ, Chailakhjan R, Latsinik N, Panasyuk A, Keiliss-Borok I. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Transplantation. 1974; 17(4): 331–40. DOI: 10.1097/00007890-197404000-00001
    Back to article
  18. 18Owen M, Friedenstein AJ. Stromal stem cells: Marrow-derived osteogenic precursors. Ciba Found Symp. 1988; 136: 42–60. DOI: 10.1002/9780470513637.ch4
    Back to article
  19. 19Haynesworth SE, Goshima J, Goldberg VM, Caplan AI. Characterization of cells with osteogenic potential from human marrow. Bone. 1992; 13(1): 81–8. DOI: 10.1016/8756-3282(92)90364-3
    Back to article
  20. 20Caplan AI. Mesenchymal stem cells. J Orthopoedic Res. 1991; 9(5): 641–50. DOI: 10.1002/jor.1100090504
    Back to article
  21. 21Caplan AI. Mesenchymal stem cells: Time to change the name! Stem Cells Transl Med. 2017; 6(6): 1445–51. DOI: 10.1002/sctm.17-0051
    Back to article
  22. 22Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: Revisiting history, concepts, and assays. Cell Stem Cell. 2008; 2(4): 313–9. DOI: 10.1016/j.stem.2008.03.002
    Back to article
  23. 23Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy [Internet]. 2006; 8(4): 315–7. DOI: 10.1080/14653240600855905
    Back to article
  24. 24Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. 1999 April; 284: 143–8. DOI: 10.1126/science.284.5411.143
    Back to article
  25. 25Zuk PA, Ph D, Zhu MIN, Mizuno H, Benhaim P, Lorenz HP. Multilineage cells from human adipose tissue: Implications for cell-based therapies. 2001; 7(2): 211–28. DOI: 10.1089/107632701300062859
    Back to article
  26. 26Zuk PA, Zhu M, Ashjian P, Ugarte DA De, Huang JI, Mizuno H, et al. Human adipose tissue is a source of multipotent stem cells. 2002 December; 13: 4279–95. DOI: 10.1091/mbc.e02-02-0105
    Back to article
  27. 27Katz AJ, Tholpady A, Tholpady SS, Shang H, Ogle RC. Cell surface and transcriptional characterization of human adipose-derived adherent stromal (hADAS) cells. Stem Cells. 2005; 23: 412–23. DOI: 10.1634/stemcells.2004-0021
    Back to article
  28. 28Witte SFHDE, Lambert EE, Merino ANA, Strini T, Douben HJCW, Flynn LO, et al. Aging of bone marrow – and umbilical cord – derived mesenchymal. Cytotherapy [Internet]; 2017 January. DOI: 10.1016/j.jcyt.2017.03.071
    Back to article
  29. 29Girdlestone J, Limbani VA, Cutler AJ, Navarrete CV. Efficient expansion of mesenchymal stromal cells from umbilical cord under low serum conditions. Cytotherapy [Internet]. 2009; 11(6): 738–48. DOI: 10.3109/14653240903079401
    Back to article
  30. 30In’t Anker PS, Scherjon SA, Kleijburg-Vander Keur C, de Groot-Swings GM, Claas FH, Fibbe WE, Kanhai HH. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells. 2004; 22(7): 1338–45. DOI: 10.1634/stemcells.2004-0058
    Back to article
  31. 31Miao Z, Jin J, Chen L, Zhu J, Huang W. Isolation of mesenchymal stem cells from human placenta: Comparison with human bone marrow mesenchymal stem cells. 2006; 30(9): 681–7. DOI: 10.1016/j.cellbi.2006.03.009
    Back to article
  32. 32Kassis I, Zangi L, Rivkin R, Levdansky L, Samuel S, Marx G, et al. Isolation of mesenchymal stem cells from G-CSF-mobilized human peripheral blood using fibrin microbeads. 2006 February; 967–76. DOI: 10.1038/sj.bmt.1705358
    Back to article
  33. 33Jahani M-A, Jahani M. In vitro isolation of stem cells derived from human dental pulp. 2010; 23–8. DOI: 10.1111/j.1399-0012.2009.01137.x
    Back to article
  34. 34Chiang E, Lai H, Chen L, Lee Y. Isolation of mesenchymal stem cells. 2011; 36(18): 1193–200. DOI: 10.1097/BRS.0b013e3182053f58
    Back to article
  35. 35Meng X, Ichim TE, Zhong J, Rogers A, Yin Z, Jackson J, et al. Endometrial regenerative cells: A novel stem cell population. 2007; 10: 1–10. DOI: 10.1186/1479-5876-5-57
    Back to article
  36. 36Macias MI, Grande J, Moreno A, Domínguez I, Bornstein R, Flores AI. BASIC SCIENCE: OBSTETRICS Isolation and characterization of true mesenchymal stem cells derived from human term decidua capable of multilineage differentiation into all 3 embryonic layers. YMOB [Internet]. 2010; 203(5): 495.e9–495.e23. DOI: 10.1016/j.ajog.2010.06.045
    Back to article
  37. 37Roubelakis MG, Pappa KI, Bitsika V, Antsaklis A, Anagnou NP. Molecular and proteomic characterization of human comparison to bone marrow mesenchymal stem cells. 2007; 951: 931–51. DOI: 10.1089/scd.2007.0036
    Back to article
  38. 38Marongiu F, Gramignoli R, Sun Q, Tahan V, Dorko K, Ellis E, et al. Isolation of amniotic mesenchymal stem cells. 2010; 1–11. DOI: 10.1002/9780470151808.sc01e05s12
    Back to article
  39. 39Poloni A, Rosini V, Mondini E, Maurizi G, Mancini S, Discepoli G, et al. Characterization and expansion of mesenchymal progenitor cells from first-trimester chorionic villi of human placenta. Cytotherapy [Internet]. 2008; 10(7): 690–7. DOI: 10.1080/14653240802419310
    Back to article
  40. 40Zeddou M, Briquet A, Relic B, Josse C, Malaise MG. The umbilical cord matrix is a better source of mesenchymal stem cells (MSC) than the umbilical cord blood. 2010; 34: 693–701. DOI: 10.1042/CBI20090414
    Back to article
  41. 41Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. British journal of haematology. 2000; 109(1): 235-42. DOI: 10.1046/j.1365-2141.2000.01986.x
    Back to article
  42. 42Lazarus HM, Haynesworth SE, Rosenthal N, Caplan AI. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells):implications for therpapeutic use. Bone marrow Transpl. 1995; 16(4): 557–64.
    Back to article
  43. 43Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999; 5(3): 309–13. DOI: 10.1038/6529
    Back to article
  44. 44Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI, Lazarus HM. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast. 2019; 18(2): 307–16. DOI: 10.1200/JCO.2000.18.2.307
    Back to article
  45. 45Chen S, Fang W, Qian J, Ye F, Liu Y, Shan S, et al. Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardal infarction. Chin Med J. 2004; 117(10): 1443–8.
    Back to article
  46. 46Sarkissian S Der, Lévesque T, Noiseux N. Optimizing stem cells for cardiac repair: Current status and new frontiers in regenerative cardiology. World J. Stem cells. 2017; 9(1): 9–25. DOI: 10.4252/wjsc.v9.i1.9
    Back to article
  47. 47Bagno L, Hatzistergos KE, Balkan W, Hare JM. Mesenchymal stem cell-based therapy for cardiovascular disease: Progress and challenges. Mol Ther [Internet]. 2018; 26(7): 1–14. DOI: 10.1016/j.ymthe.2018.05.009
    Back to article
  48. 48Orlic D, Kajstura J, Chimenti S, Dm B, Leri A, Anversa P. Bone marrow stem cells regenerate infarcted myocardium. 2003; 7: 86–8. DOI: 10.1034/j.1399-3046.7.s3.13.x
    Back to article
  49. 49Chen S, Fang W, Ye F, Liu Y, Qian J, Shan S, et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am. J. Cardio. 2004; 94(1): 92–5. DOI: 10.1016/j.amjcard.2004.03.034
    Back to article
  50. 50Zimmet JM, Hare JM. FOCUSED ISSUE: Cardiac repair by stem cells emerging role for bone marrow derived mesenchymal stem cells in myocardial regenerative therapy. Basic Res. Cardol. 2005; 481: 471–81. DOI: 10.1007/s00395-005-0553-4
    Back to article
  51. 51Banerjee MN, Bolli R, Hare JM. Clinical studies of cell therapy in cardiovascular medicine recent developments and future directions. Circ. Res. 2018; 016960: 266–88. DOI: 10.1161/CIRCRESAHA.118.311217
    Back to article
  52. 52Hare J, Fishman J, Gerstenblith G, Difede Velazquez D, Zambrano J, Suncion V, et al. Comparison of allogeneic vs. autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The POSEIDON randomized trial. JAMA. 2012; 308(22): 2369–79. DOI: 10.1001/jama.2012.25321
    Back to article
  53. 53Mathiasen AB, Qayyum AA, Jørgensen E, Helqvist S, Fischer-nielsen A, Kofoed KF, et al. Interventional cardiology bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: A randomized placebo-controlled trial. Eur. Heart. J. 2015; 36(27): 1744–53. DOI: 10.1093/eurheartj/ehv136
    Back to article
  54. 54Oh H, Bradfute SB, Gallardo TD, Nakamura T, Gaussin V, Mishina Y, et al. Cardiac progenitor cells from adult myocardium: Homing, differentiation, and fusion after infarction. Proc Natl Acad Sci USA. 2003; 100(21): 12313–8. DOI: 10.1073/pnas.2132126100
    Back to article
  55. 55Quevedo HC, Hatzistergos KE, Oskouei BN, Feigenbaum GS, Rodriguez JE, Valdes D, et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci USA. 2009; 106(33): 14022–7. DOI: 10.1073/pnas.0903201106
    Back to article
  56. 56Szaraz P, Gratch YS, Iqbal F, Librach CL. In vitro differentiation of human mesenchymal stem cells into functional cardiomyocyte-like cells. J Vis Exp. 2017; 2017(126): 1–14. DOI: 10.3791/55757
    Back to article
  57. 57Jeong H, Yim HW, Park HJ, Cho Y, Hong H, Kim NJ, et al. Mesenchymal stem cell therapy for ischemic heart disease: Systematic review and meta-analysis. Int J Stem Cells. 2018; 11(1): 1–12. DOI: 10.15283/ijsc17061
    Back to article
  58. 58Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Mediine. 2005; 11(4): 367–8. DOI: 10.1038/nm0405-367
    Back to article
  59. 59Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008; 103(11): 1204–19. DOI: 10.1161/CIRCRESAHA.108.176826
    Back to article
  60. 60Boyle AJ, McNiece IK, Hare JM. Mesenchymal stem cell therapy for cardiac repair. Methods Mol Biol. 2010; 660: 65–84. DOI: 10.1007/978-1-60761-705-1_5
    Back to article
  61. 61Hatzistergos KE, Quevedo H, Oskouei BN, Hu Q, Feigenbaum GS, Margitich IS, et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res. 2010; 107(7): 913–22. DOI: 10.1161/CIRCRESAHA.110.222703
    Back to article
  62. 62Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009; 54(24): 2277–86. DOI: 10.1016/j.jacc.2009.06.055
    Back to article
  63. 63Karantalis V, Difede DL, Gerstenblith G, Pham S, Symes J, Zambrano JP, et al. Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The prospective randomized study of mesenchymal stem cells. Circ Res. 2014; 114(8): 1302–10. DOI: 10.1161/CIRCRESAHA.114.303180
    Back to article
  64. 64Karantalis V, Hare JM. Use of mesenchymal stem cells for therapy of cardiac disease. Circ Res. 2015; 116(8): 1413–30. DOI: 10.1161/CIRCRESAHA.116.303614
    Back to article
  65. 65Eschenhagen T, Bolli R, Braun T, Field LJ, Fleischmann BK, Frisén J, et al. Cardiomyocyte regeneration: A consensus statement. Circulation. 2017; 136(7): 680–6. DOI: 10.1161/CIRCULATIONAHA.117.029343
    Back to article
  66. 66Perin EC, Borow KM, Silva G V., DeMaria AN, Marroquin OC, Huang PP, et al. A Phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure. Circulation Research. 2015; 117: 576–584. DOI: 10.1161/CIRCRESAHA.115.306332
    Back to article
  67. 67Guo Y, Yu Y, Hu S, Chen Y, Shen Z. The therapeutic potential of mesenchymal stem cells for cardiovascular diseases. Cell Death Dis [Internet]. 2020; 11(5): 1–10. DOI: 10.1038/s41419-020-2542-9
    Back to article
  68. 68Hare JM, Fishman JE, Heldman AW. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy. J Autism Dev Disord. 2017; 47(3): 549–62.
    Back to article
  69. 69Heldman AW, Difede DL, Fishman JE, Juan P, Trachtenberg BH, Karantalis V, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: The TAC-HFT Randomized Trial. JAMA. 2015; 311(1): 62–73. DOI: 10.1001/jama.2013.282909
    Back to article
  70. 70Boyle AJ, McNiece IK, Hare JM. Mesenchymal stem cell therapy for cardiac repair. Methods Mol Biol. 2010; 660(24): 65–84. DOI: 10.1007/978-1-60761-705-1_5
    Back to article
  71. 71Bartolucci J, Verdugo FJ, González PL, Larrea RE, Abarzua E, Goset C, et al. Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: A phase 1/2 randomized controlled trial (RIMECARD trial [Randomized clinical trial of intravenous infusion umbilical cord mesenchymal Stem Cells on Cardiopathy]). Circ Res. 2017; 121(10): 1192–204. DOI: 10.1161/CIRCRESAHA.117.310712
    Back to article
  72. 72Butler J, Epstein SE, Greene SJ, Quyyumi AA, Sikora S, Kim RJ, et al. Intravenous allogeneic mesenchymal stem cells for nonischemic cardiomyopathy: Safety and efficacy results of a Phase II-A randomized trial. Circ Res. 2017; 120(2): 332–40. DOI: 10.1161/CIRCRESAHA.116.309717
    Back to article
  73. 73Grossman PM, Han Z, Palasis M, Barry JJ, Lederman RJ. Incomplete retention after direct myocardial injection. Catheter Cardiovasc Interv. 2002; 55(3): 392–7. DOI: 10.1002/ccd.10136
    Back to article
  74. 74Amado LC, Saliaris AP, Schuleri KH, St. John M, Xie JS, Cattaneo S, et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci USA. 2005; 102(32): 11474–9. DOI: 10.1073/pnas.0504388102
    Back to article
  75. 75Rodrigo SF, Van Ramshorst J, Hoogslag GE, Boden H, Velders MA, Cannegieter SC, et al. Intramyocardial injection of autologous bone marrow-derived ex vivo expanded mesenchymal stem cells in acute myocardial infarction patients is feasible and safe up to 5 years of follow-up. J Cardiovasc Transl Res. 2013; 6(5): 816–25. DOI: 10.1007/s12265-013-9507-7
    Back to article
  76. 76Guijarro D, Lebrin M, Lairez O, Bourin P, Piriou N, Pozzo J, et al. Intramyocardial transplantation of mesenchymal stromal cells for chronic myocardial ischemia and impaired left ventricular function: Results of the MESAMI 1 pilot trial. Int J Cardiol [Internet]. 2016; 209: 258–65. DOI: 10.1016/j.ijcard.2016.02.016
    Back to article
  77. 77Gao LR, Pei XT, Ding QA, Chen Y, Zhang NK, Chen HY, et al. A critical challenge: Dosage-related efficacy and acute complication intracoronary injection of autologous bone marrow mesenchymal stem cells in acute myocardial infarction. Int J Cardiol [Internet]. 2013; 168(4): 3191–9. DOI: 10.1016/j.ijcard.2013.04.112
    Back to article
  78. 78Liu C-B, Huang H, Sun P, Ma S-Z, Liu A-H, Xue J, et al. Human umbilical cord-derived mesenchymal stromal cells improve left ventricular function, perfusion, and remodeling in a porcine model of chronic myocardial ischemia. Stem Cells Transl Med. 2016; 5(8): 1004–13. DOI: 10.5966/sctm.2015-0298
    Back to article
  79. 79Vilahur G, Oñate B, Cubedo J, Béjar MT, Arderiu G, Peña E, et al. Allogenic adipose-derived stem cell therapy overcomes ischemia-induced microvessel rarefaction in the myocardium: Systems biology study. Stem Cell Res Ther. 2017; 8(1): 1–15. DOI: 10.1186/s13287-017-0509-2
    Back to article
  80. 80Fakoya AOJ. New delivery systems of stem cells for vascular regeneration in ischemia. Front Cardiovasc Med. 2017 February; 4: 1–20. DOI: 10.3389/fcvm.2017.00007
    Back to article
  81. 81Kanelidis AJ, Premer C, Lopez J, Balkan W, Hare JM. Route of delivery modulates the efficacy of mesenchymal stem cell therapy for myocardial infarction: A meta-analysis of preclinical studies and clinical trials. Physiol Behav. 2017; 120(7): 1139–50. DOI: 10.1161/CIRCRESAHA.116.309819
    Back to article
  82. 82Poe AJ, Knowlton AA. Exosomes as agents of change in the cardiovascular system. J Mol Cell Cardiol. 2017; 111: 40–50. DOI: 10.1016/j.yjmcc.2017.08.002
    Back to article
  83. 83Zhang Z, Yang J, Yan W, Li Y, Shen Z, Asahara T. Pretreatment of cardiac stem cells with exosomes derived from mesenchymal stem cells enhances myocardial repair. J Am Heart Assoc. 2016; 5(1): 1–16. DOI: 10.1161/JAHA.115.002856
    Back to article
  84. 84Ju C, Shen Y, Ma G, Liu Y, Cai J, Kim I, et al. Transplantation of cardiac mesenchymal stem cell-derived exosomes promotes repair in ischemic myocardium. J Cardiovasc Transl Res. 2018; 11(5): 420–8. DOI: 10.1007/s12265-018-9822-0
    Back to article
  85. 85Qiu G, Zheng G, Ge M, Wang J, Huang R, Shu Q, et al. Mesenchymal stem cell-derived extracellular vesicles affect disease outcomes via transfer of microRNAs. Stem Cell Res Ther. 2018; 9(1): 1–9. DOI: 10.1186/s13287-018-1069-9
    Back to article
  86. 86Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res. 2004; 94(5): 678–85. DOI: 10.1161/01.RES.0000118601.37875.AC
    Back to article
  87. 87Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove CJ, Bovenkerk JE, et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation. 2004; 109(10): 1292–8. DOI: 10.1161/01.CIR.0000121425.42966.F1
    Back to article
  88. 88Iso Y, Spees JL, Serrano C, Bakondi B, Pochampally R, Song Y-H, et al. Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. Biochem Biophys Res. 2007; 354(3): 700–6. DOI: 10.1016/j.bbrc.2007.01.045
    Back to article
  89. 89Shi S, Wu X, Wang X, Hao W, Miao H, Zhen L, et al. Differentiation of bone marrow mesenchymal stem cells to cardiomyocyte-like cells is regulated by the combined low dose treatment of transforming growth Factor-1 and 5-Azacytidine. Stem Cells Int; 2016. Article ID: 3816256. DOI: 10.1155/2016/3816256
    Back to article
  90. 90Chen Z, Chen L, Zeng C, Wang WE. Functionally improved mesenchymal stem cells to better treat myocardial infarction. Stem Cells Int; 2018. Article ID: 7045245. DOI: 10.1155/2018/7045245
    Back to article
  91. 91Chen Y, Zuo J, Chen W, Yang Z, Zhang Y, Hua F, et al. The enhanced effect and underlying mechanisms of mesenchymal stem cells with IL-33 overexpression on myocardial infarction. Stem Cell Res Ther. 2019; 10(1): 1–14. DOI: 10.1186/s13287-018-1105-9
    Back to article
  92. 92Liu XH, Bai CG, Xu ZY, Huang SD, Yuan Y, Gong DJ, et al. Therapeutic potential of angiogenin modified mesenchymal stem cells: Angiogenin improves mesenchymal stem cells survival under hypoxia and enhances vasculogenesis in myocardial infarction. Microvasc Res. 2008; 76(1): 23–30. DOI: 10.1016/j.mvr.2008.02.005
    Back to article
  93. 93Muraya K, Kawasaki T, Yamamoto T, Akutsu H. Enhancement of cellular adhesion and proliferation in human mesenchymal stromal cells by the direct addition of recombinant collagen i peptide to the culture medium. Biores Open Access. 2019; 8(1): 210–8. DOI: 10.1089/biores.2019.0012
    Back to article
  94. 94Zhao L, Liu X, Zhang Y, Liang X, Ding Y, Xu Y. Enhanced cell survival and paracrine effects of mesenchymal stem cells overexpressing hepatocyte growth factor promote cardioprotection in myocardial infarction. Exp Cell Res [Internet]. 2016; 344(1): 30–9. DOI: 10.1016/j.yexcr.2016.03.024
    Back to article
  95. 95Mias C, Lairez O, Trouche E, Roncalli J, Calise D, Seguelas MH, et al. Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction. Stem Cells. 2009; 27(11): 2734–43. DOI: 10.1002/stem.169
    Back to article
  96. 96Ma T, Chen Y, Chen Y, Meng Q, Sun J, Shao L, et al. MicroRNA-132, delivered by mesenchymal stem cell-derived exosomes, promote angiogenesis in myocardial infarction. Stem Cells Int; 2018. Article Id: 3290372. DOI: 10.1155/2018/3290372
    Back to article
  97. 97Rogers TB, Pati S, Gaa S, Riley D, Khakoo AY, Patel S, et al. Mesenchymal stem cells stimulate protective genetic reprogramming of injured cardiac ventricular myocytes. J Mol Cell Cardiol [Internet]. 2011; 50(2): 346–56. DOI: 10.1016/j.yjmcc.2010.09.001
    Back to article
  98. 98Noiseux N, Gnecchi M, Lopez-Ilasaca M, Zhang L, Solomon SD, Deb A, et al. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther. 2006; 14(6): 840–50. DOI: 10.1016/j.ymthe.2006.05.016
    Back to article
  99. 99Bai T, Liu F, Zou F, Zhao G, Jiang Y, Liu L, et al. Epidermal growth factor induces proliferation of hair follicle-derived mesenchymal stem cells through epidermal growth factor receptor-mediated activation of erk and akt signaling pathways associated with upregulation of cyclin d1 and downregulation of p1. Stem Cells Dev. 2017; 26(2): 113–22. DOI: 10.1089/scd.2016.0234
    Back to article
  100. 100Ward MR, Abadeh A, Connelly KA. Concise review: Rational use of mesenchymal stem cells in the treatment of ischemic heart disease. Stem Cells Transl Med. 2018; 7(7): 543–50. DOI: 10.1002/sctm.17-0210
    Back to article
  101. 101Nakanishi C, Yamagishi M, Yamahara K, Hagino I, Mori H, Sawa Y, et al. Activation of cardiac progenitor cells through paracrine effects of mesenchymal stem cells. Biochem Biophys Res Commun. 2008; 374(1): 11–6. DOI: 10.1016/j.bbrc.2008.06.074
    Back to article
  102. 102Cho J, Zhai P, Maejima Y, Sadoshima J. Myocardial injection with GSK-3β-overexpressing bone marrow-derived mesenchymal stem cells attenuates cardiac dysfunction after myocardial infarction. Circ Res. 2011; 108(4): 478–89. DOI: 10.1161/CIRCRESAHA.110.229658
    Back to article
  103. 103Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med. 2005; 11(4): 367–8. DOI: 10.1038/nm0405-367
    Back to article
  104. 104Takahashi M, Li TS, Suzuki R, Kobayashi T, Ito H, Ikeda Y, et al. Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury. Am J Physiol – Hear Circ Physiol. 2006; 291(2): 886–93. DOI: 10.1152/ajpheart.00142.2006
    Back to article
  105. 105Silva DN, Souza BSF, Azevedo CM, Vasconcelos JF, De Jesus PG, Feitoza MS, et al. IGF-1-Overexpressing mesenchymal stem/stromal cells promote immunomodulatory and proregenerative effects in chronic experimental chagas disease. Stem Cells Int; 2018. Article Id: 9108681. DOI: 10.1155/2018/9108681
    Back to article
  106. 106Feng J, Wu Y, Chen W, Li J, Wang X, Chen Y, et al. Sustained release of bioactive IGF-1 from a silk fibroin microsphere-based injectable alginate hydrogel for the treatment of myocardial infarction. J Mater Chem B. 2020; 8(2): 308–15. DOI: 10.1039/C9TB01971E
    Back to article
  107. 107Gallina C, Turinetto V, Giachino C. A new paradigm in cardiac regeneration: The mesenchymal stem cell secretome. Stem Cells Int; 2015. Article Id: 765846. DOI: 10.1155/2015/765846
    Back to article
  108. 108Collino F, Deregibus MC, Bruno S, Sterpone L, Aghemo G, Viltono L, et al. Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs. PLoS One. 2010; 5(7): e11803. DOI: 10.1371/journal.pone.0011803
    Back to article
  109. 109Li B, Zeng Q, Wang H, Shao S, Mao X, Zhang F, et al. Adipose tissue stromal cells transplantation in rats of acute myocardial infarction. Coron Artery Dis. 2007; 18(3): 221–7. DOI: 10.1097/MCA.0b013e32801235da
    Back to article
  110. 110Zhu W, Huang L, Li Y, Zhang X, Gu J, Yan Y, et al. Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo. Cancer Lett [Internet]. 2012; 315(1): 28–37. DOI: 10.1016/j.canlet.2011.10.002
    Back to article
  111. 111Tomasoni S, Longaretti L, Rota C, Morigi M, Conti S, Gotti E, et al. Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells. Stem Cells Dev. 2013; 22(5): 772–80. DOI: 10.1089/scd.2012.0266
    Back to article
  112. 112Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9(6): 654–9. DOI: 10.1038/ncb1596
    Back to article
  113. 113Yuan A, Farber EL, Rapoport AL, Tejada D, Deniskin R, Akhmedov NB, et al. Transfer of microRNAs by embryonic stem cell microvesicles. PLoS One. 2009; 4(3). DOI: 10.1371/journal.pone.0004722
    Back to article
  114. 114Feng Y, Huang W, Wani M, Yu X, Ashraf M. Ischemic preconditioning potentiates the protective effect of stem cells through secretion of exosomes by targeting Mecp2 via miR-22. PLoS One. 2014; 9(2): 1–8. DOI: 10.1371/journal.pone.0088685
    Back to article
  115. 115Lai RC, Arslan F, Lee MM, Sze NSK, Choo A, Chen TS, et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res [Internet]. 2010; 4(3): 214–22. DOI: 10.1016/j.scr.2009.12.003
    Back to article
  116. 116Lai RC, Tan SS, Teh BJ, Sze SK, Arslan F, de Kleijn DP, et al. Proteolytic potential of the MSC exosome proteome: Implications for an exosome-mediated delivery of therapeutic proteasome. Int J Proteomics. 2012; 1–14. DOI: 10.1155/2012/971907
    Back to article
  117. 117Yu B, Gong M, Wang Y, Millard RW, Pasha Z, Yang Y, et al. Cardiomyocyte protection by GATA-4 gene engineered mesenchymal stem cells is partially mediated by translocation of miR-221 in microvesicles. PLoS One. 2013; 8(8): 1–11. DOI: 10.1371/journal.pone.0073304
    Back to article
  118. 118Huang P, Wang L, Li Q, Xu J, Xu J, Xiong Y, et al. Combinatorial treatment of acute myocardial infarction using stem cells and their derived exosomes resulted in improved heart performance. Stem Cell Res Ther. 2019; 10(1): 1–12. DOI: 10.1186/s13287-019-1353-3
    Back to article
  119. 119Zlatanova I, Pinto C, Silvestre JS. Immune modulation of cardiac repair and regeneration: The art of mending broken hearts. Front Cardiovasc Med. 2016 October; 3: 1–8. DOI: 10.3389/fcvm.2016.00040
    Back to article
  120. 120Suncion VY, Ghersin E, Fishman JE, Zambrano JP, Mandel N, Nelson KH, et al. Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally? An analysis from the POSEIDON randomized trial. Circ Res. 2014; 114(8): 1292–301. DOI: 10.1161/CIRCRESAHA.114.302854
    Back to article
  121. 121Maggini J, Mirkin G, Bognanni I, Holmberg J, Piazzón IM, Nepomnaschy I, et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One. 2010; 5(2): e9252. DOI: 10.1371/journal.pone.0009252
    Back to article
  122. 122Van Den Akker F, De Jager SCA, Sluijter JPG. Mesenchymal stem cell therapy for cardiac inflammation: Immunomodulatory properties and the influence of toll-like receptors. Mediators Inflamm; 2013. Article Id: 181020. DOI: 10.1155/2013/181020
    Back to article
  123. 123Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell [Internet]. 2009; 5(1): 54–63. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624763/pdf/nihms412728.pdf. DOI: 10.1016/j.stem.2009.05.003
    Back to article
  124. 124Ke D, Fang J, Fan L, Chen Z, Chen L. Regulatory T cells contribute to rosuvastatin-induced cardioprotection against ischemia-reperfusion injury. Coron Artery Dis. 2013; 24(4): 334–41. DOI: 10.1097/MCA.0b013e3283608c12
    Back to article
  125. 125Lemcke H, Voronina N, Steinhoff G, David R. Recent progress in stem cell modification for cardiac regeneration. Stem Cells Int; 2018. Article Id: 1909346. DOI: 10.1155/2018/1909346
    Back to article
  126. 126Tompkins BA, Balkan W, Winkler J, Gyöngyösi M, Goliasch G, Fernández-Avilés F, et al. IMPACT: Preclinical studies of cell therapy for human disease. Circ Res. 2018; 122(7): 1006–20. DOI: 10.1161/CIRCRESAHA.117.312486
    Back to article
  127. 127Recchia FA, Lionetti V. Animal models of dilated cardiomyopathy for translational research. Vet Res Commun. 2007; 31(SUPPL. 1): 35–41. DOI: 10.1007/s11259-007-0005-8
    Back to article
  128. 128Mu Y, Cao G, Zeng Q, Li Y. Transplantation of induced bone marrow mesenchymal stem cells improves the cardiac function of rabbits with dilated cardiomyopathy via upregulation of vascular endothelial growth factor and its receptors. Exp Biol Med. 2011; 236(9): 1100–7. DOI: 10.1258/ebm.2011.011066
    Back to article
  129. 129Zhang C, Zhou G, Chen Y, Liu S, Chen F, Xie L, et al. Human umbilical cord mesenchymal stem cells alleviate interstitial fibrosis and cardiac dysfunction in a dilated cardiomyopathy rat model by inhibiting TNF-α and TGF-β1/ERK1/2 signaling pathways. Mol Med Rep. 2018; 17(1): 71–8. DOI: 10.3892/mmr.2017.7882
    Back to article
  130. 130Narita T, Suzuki K. Bone marrow-derived mesenchymal stem cells for the treatment of heart failure. Heart Fail Rev. 2015; 20(1): 53–68. DOI: 10.1007/s10741-014-9435-x
    Back to article
  131. 131Kanelidis AJ, Premer C, Lopez J, Balkan W, Hare JM. Route of delivery modulates the efficacy of mesenchymal stem cell therapy for myocardial infarction: A meta-analysis of preclinical studies and clinical trials. Circ Res. 2017; 120(7): 1139–50. DOI: 10.1161/CIRCRESAHA.116.309819
    Back to article
  132. 132Ciszek B, Skubiszewska D, Ratajska A. The anatomy of the cardiac veins in mice. J Anat. 2007; 211(1): 53–63. DOI: 10.1111/j.1469-7580.2007.00753.x
    Back to article
  133. 133Price MJ, Chou CC, Frantzen M, Miyamoto T, Kar S, Lee S, et al. Intravenous mesenchymal stem cell therapy early after reperfused acute myocardial infarction improves left ventricular function and alters electrophysiologic properties. Int J Cardiol. 2006; 111(2): 231–9. DOI: 10.1016/j.ijcard.2005.07.036
    Back to article
  134. 134Qi C, Ma G, Liu N, Shen C, Chen Z, Liu X, et al. Transplantation of magnetically labeled mesenchymal stem cells improves cardiac function in a swine myocardial infarction model. Chin Med J (Engl). 2008; 121(6): 544–50. DOI: 10.1097/00029330-200803020-00016
    Back to article
  135. 135Cheng Y, Yi G, Conditt GB, Sheehy A, Kolodgie FD, Tellez A, et al. Catheter-based endomyocardial delivery of mesenchymal precursor cells using 3D echo guidance improves cardiac function in a chronic myocardial injury ovine model. Cell Transplant. 2013; 22(12): 2299–309. DOI: 10.3727/096368912X658016
    Back to article
  136. 136Vasileios Karantalis M, Viky Y, Suncion-Loescher M, Luiza Bagno P, Samuel Golpanian M, Ariel Wolf B, Cristina Sanina M, et al. Synergistic effects of combined cell therapy for chronic ischemic cardiomyopathy. 2015; 66(18): 1990–9. DOI: 10.1016/j.jacc.2015.08.879
    Back to article
  137. 137Bobi J, Solanes N, Fernández-Jiménez R, Galán-Arriola C, Dantas AP, Fernández-Friera L, et al. Intracoronary administration of allogeneic adipose tissue-derived mesenchymal stem cells improves myocardial perfusion but not left ventricle function, in a translational model of acute myocardial infarction. J Am Heart Assoc. 2017; 6(5): 1–17. DOI: 10.1161/JAHA.117.005771
    Back to article
  138. 138Lim M, Wang W, Liang L, Han ZB, Li Z, Geng J, et al. Intravenous injection of allogeneic umbilical cord-derived multipotent mesenchymal stromal cells reduces the infarct area and ameliorates cardiac function in a porcine model of acute myocardial infarction. Stem Cell Res Ther. 2018; 9(1): 1–17. DOI: 10.1186/s13287-018-0888-z
    Back to article
  139. 139Kumar M, Kasala ER, Bodduluru LN, Dahiya V, Sharma D, Kumar V, et al. Animal models of myocardial infarction: Mainstay in clinical translation. Regul Toxicol Pharmacol [Internet]. 2016; 76: 221–30. DOI: 10.1016/j.yrtph.2016.03.005
    Back to article
  140. 140Karantalis V, Difede DL, Gerstenblith G, Pham S, Symes J, Zambrano JP, et al. Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion and fibrotic burden when administered to patients undergoing coronary artery bypass grafting – The PROMETHEUS Trial Vasileios. Circ Res. 2014; 114(8): 1302–10. DOI: 10.1161/CIRCRESAHA.114.303180
    Back to article
  141. 141Florea V, Rieger AC, DiFede DL, El-Khorazaty J, Natsumeda M, Banerjee MN, et al. Dose comparison study of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy (The TRIDENT study). Circ Res. 2017; 121(11): 1279–90. DOI: 10.1161/CIRCRESAHA.117.311827
    Back to article
  142. 142Perin EC, Sanz-Ruiz R, Sánchez PL, Lasso J, Pérez-Cano R, Alonso-Farto JC, et al. Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE Trial. Am Heart J [Internet]. 2014; 168(1): 88–95. DOI: 10.1016/j.ahj.2014.03.022
    Back to article
  143. 143Chugh AR, Zuba-Surma EK, Dawn B. Bone marrow-derived mesenchymal stems cells and cardiac repair. Minerva Cardioangiol. 2009; 57(2): 185–202.
    Back to article
  144. 144Dawn B, Abdel-Latif A, Sanganalmath SK, Flaherty MP, Zuba–Surma EKA. Cardiac repair with adult bone marrow-derived cells: The clinical evidence. Antioxidants Redox Signal. 2009; 57(2): 185–202. DOI: 10.1089/ars.2009.2462
    Back to article
  145. 145Sanz-Ruiz R, Fernández-Avilés F. Autologous and allogeneic cardiac stem cell therapy for cardiovascular diseases. Pharmacol Res [Internet]. 2018; 127: 92–100. DOI: 10.1016/j.phrs.2017.05.024
    Back to article
  146. 146Xu W, Zhang X, Qian H, Zhu W, Sun X, Hu J, et al. Mesenchymal stem cells from adult human bone marrow differentiate into a cardiomyocyte phenotype in vitro. Exp Biol Med. 2004; 229(7): 623–31. DOI: 10.1177/153537020422900706
    Back to article
  147. 147Shim WSN, Jiang S, Wong P, Tan J, Chua YL, Seng Tan Y, et al. Ex vivo differentiation of human adult bone marrow stem cells into cardiomyocyte-like cells. Biochem Biophys Res Commun. 2004; 324(2): 481–8. DOI: 10.1016/j.bbrc.2004.09.087
    Back to article
  148. 148Oswald J, Boxberger S, Joergensen B, Bornhaeuser M, Ehninger G, Werner C. Mesenchymal stem cells (MSC) can be differentiated into endothelial cells in vitro. Trans – 7th World Biomater Congr. 2004; 506. DOI: 10.1634/stemcells.22-3-377
    Back to article
  149. 149Lin CS, Xin ZC, Dai J, Lue TF. Commonly used mesenchymal stem cell markers and tracking labels: Limitations and challenges. Histol Histopathol. 2013; 28(9): 1109–16.
    Back to article
  150. 150Mazhari R, Hare JM. Mechanisms of action of mesenchymal stem cells in cardiac repair: Potential influences on the cardiac stem cell niche. Nat Clin Pract Cardiovasc Med. 2007; 4(SUPPL. 1): 21–6. DOI: 10.1038/ncpcardio0770
    Back to article
  151. 151Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008; 103(11): 1204–19. DOI: 10.1161/CIRCRESAHA.108.176826
    Back to article
  152. 152Teng X, Chen L, Chen W, Yang J, Yang Z, Shen Z. Mesenchymal stem cell-derived exosomes improve the microenvironment of infarcted myocardium contributing to angiogenesis and anti-inflammation. Cell Physiol Biochem. 2015; 37(6): 2415–24. DOI: 10.1159/000438594
    Back to article
  153. 153Jin-Ok Jeong, MD P, Ji Woong Han P, Jin-Man Kim, MD P, Hyun-Jai Cho, MD P, Changwon Park P, Namho Lee MDP, et al. Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy. Circ Res. 2011; 108(11): 1340–7. DOI: 10.1161/CIRCRESAHA.110.239848
    Back to article
  154. 154Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, Nygren JM, et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood. 2007; 110(4): 1362–9. DOI: 10.1182/blood-2006-12-063412
    Back to article
  155. 155Liao J, Chen X, Li Y, Ge Z, Duan H, Zou Y, et al. Transfer of bone-marrow-derived mesenchymal stem cells influences vascular remodeling and calcification after balloon injury in hyperlipidemic rats. J Biomed Biotechnol; 2012. Article Id: 165296. DOI: 10.1155/2012/165296
    Back to article
  156. 156Denu RA, Nemcek S, Bloom DD, Goodrich AD, Kim J, Mosher DF, et al. Fibroblasts and mesenchymal stromal/stem cells are phenotypically indistinguishable. Acta Haematol. 2016; 136(2): 85–9. DOI: 10.1159/000445096
    Back to article
  157. 157Sacchetti B, Funari A, Remoli C, Giannicola G, Kogler G, Liedtke S, et al. No identical “mesenchymal stem cells” at different times and sites: Human committed progenitors of distinct origin and differentiation potential are incorporated as adventitial cells in microvessels. Stem Cell Reports [Internet]. 2016; 6(6): 897–913. DOI: 10.1016/j.stemcr.2016.05.011
    Back to article
  158. 158Hematti P. Mesenchymal stromal cells and fibroblasts: A case of mistaken identity? Cytotherapy. 2012; 14(5): 516–21. DOI: 10.3109/14653249.2012.677822
    Back to article
  159. 159Musialek P, Mazurek A, Kwiecien E, Drabik L, Tekieli L, Szot W, et al. Safety and high-grade myocardial uptake of Whartons Jelly Plurioptent Stem Cells transcoronary transfer in acute myocardial infarction in man. Eur Heart J. 2017; 38: 4027. DOI: 10.1093/eurheartj/ehx504.P4027
    Back to article
  160. 160Kandala J, Upadhyay GA, Pokushalov E, Wu S, Drachman DE, Singh JP. Meta-analysis of stem cell therapy in chronic ischemic cardiomyopathy. Am J Cardiol [Internet]. 2013; 112(2): 217–25. DOI: 10.1016/j.amjcard.2013.03.021
    Back to article
  161. 161Cleland JGF, Pennell DJ, Ray SG, Coats AJ, Macfarlane PW, Murray GD, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): Randomised controlled trial. Lancet. 2003; 362(9377): 14–21. DOI: 10.1016/S0140-6736(03)13801-9
    Back to article
  162. 162Wong M, Staszewsky L, Latini R, Barlera S, Glazer R, Aknay N, et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data. J Am Coll Cardiol. 2004; 43(11): 2022–7. DOI: 10.1016/j.jacc.2003.12.053
    Back to article
  163. 163Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: A systematic review of randomized clinical trials. Eur Heart J. 2009; 30(4): 469–77. DOI: 10.1093/eurheartj/ehn543
    Back to article
  164. 164Hematol J, Zhou T, Yuan Z, Weng J, Pei D, Du X, et al. Challenges and advances in clinical applications of mesenchymal stromal cells. J Hematol Oncol [Internet]. 2021; 1–24. DOI: 10.1186/s13045-021-01037-x
    Back to article
  165. 165Razeghian-jahromi I, Matta AG, Canitrot R, Zibaeenezhad MJ, Razmkhah M, Safari A, et al. Surfing the clinical trials of mesenchymal stem cell therapy in ischemic cardiomyopathy. 2021; 1: 1–12. DOI: 10.1186/s13287-021-02443-1
    Back to article
  166. 166Shani NN, Levin-Kotler L-P, Palevski D, Amit U, Kain D, Landa N, et al. Left ventricular dysfunction switches mesenchymal stromal cells toward an inflammatory phenotype and impairs their reparative properties via toll-like receptor-4. Circulation. 2017; 2271–87. DOI: 10.1161/CIRCULATIONAHA.116.023527
    Back to article
  167. 167Zhang M, Mal N, Kiedrowski M, Chacko M, Askari AT, Popovic ZB, et al. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J. 2007; 21(12): 3197–207. DOI: 10.1096/fj.06-6558com
    Back to article
  168. 168Karpov AA, Udalova DV, Pliss MG, Galagudza MM. Can the outcomes of mesenchymal stem cell-based therapy for myocardial infarction be improved? Providing weapons and armour to cells. Cell Prolif. 2017; 50(2): 1–16. DOI: 10.1111/cpr.12316
    Back to article
  169. 169Gonzalez-King H, García NA, Ontoria-Oviedo I, Ciria M, Montero JA, Sepúlveda P. Hypoxia inducible factor-1α potentiates jagged 1-mediated angiogenesis by mesenchymal stem cell-derived exosomes. Stem Cells. 2017; 35(7): 1747–59. DOI: 10.1002/stem.2618
    Back to article
  170. 170Hahn JY, Cho HJ, Kang HJ, Kim TS, Kim MH, Chung JH, et al. Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J Am Coll Cardiol. 2008; 51(9): 933–43. DOI: 10.1016/j.jacc.2007.11.040
    Back to article
  171. 171Blocki A, Beyer S, Dewavrin JY, Goralczyk A, Wang Y, Peh P, et al. Microcapsules engineered to support mesenchymal stem cell (MSC) survival and proliferation enable long-term retention of MSCs in infarcted myocardium. Biomaterials [Internet]. 2015; 53: 12–24. DOI: 10.1016/j.biomaterials.2015.02.075
    Back to article
  172. 172Kai D, Wang QL, Wang HJ, Prabhakaran MP, Zhang Y, Tan YZ, et al. Stem cell-loaded nanofibrous patch promotes the regeneration of infarcted myocardium with functional improvement in rat model. Acta Biomater [Internet]. 2014; 10(6): 2727–38. DOI: 10.1016/j.actbio.2014.02.030
    Back to article
  173. 173Chu J, Shi P, Yan W, Fu J, Yang Z, He C, et al. PEGylated graphene oxide-mediated quercetin modified collagen hybrid scaffold for enhancement of MSCs differentiation potential and diabetic wound healing. Nanoscale. 2018; 10(20): 9547–60. DOI: 10.1039/C8NR02538J
    Back to article
  174. 174Chen Z, Chen L, Zeng C, Wang WE. Functionally improved mesenchymal stem cells to better treat myocardial infarction. Stem Cells Int. 2018. Article Id: 7045245. DOI: 10.1155/2018/7045245
    Back to article
DOI: https://doi.org/10.5334/gh.1098 | Journal eISSN: 2211-8179
Journal RSS Feed
Language: English
Submitted on: Nov 5, 2021
Accepted on: Jan 26, 2022
Published on: Mar 8, 2022
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
ischemic heart disease,
mesenchymal stem cells,
cardiac regeneration

© 2022 Merlin Sobia Poomani, Iyyadurai Mariappan, Ramachandran Perumal, Rathika Regurajan, Krishnaveni Muthan, Venkatesh Subramanian, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 17 (2022): Issue 1Next article